Last update 08 May 2025

GPR39 x JAK2

Basic Info

Related Targets
GPR39JAK2

Related

1
Drugs associated with GPR39 x JAK2
Gandotinib
Target
GPR39 x JAK2
Mechanism
GPR39 agonists [+1]
Active Org.
Eli Lilly & Co.Eli Lilly & Co.
Originator Org.
Eli Lilly & Co.Eli Lilly & Co.
Active Indication
Mycosis Fungoides [+3]
Inactive Indication
JAK-2 V617F Positive Myeloproliferative Disorders [+1]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
3
Clinical Trials associated with GPR39 x JAK2
NCT01520220
/ CompletedPhase 1
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
NCT01594723
/ Active, not recruitingPhase 2
A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms
NCT01134120
/ CompletedPhase 1
A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders
100 Clinical Results associated with GPR39 x JAK2
Login to view more data
100 Translational Medicine associated with GPR39 x JAK2
Login to view more data
0 Patents (Medical) associated with GPR39 x JAK2
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free